IDSA News - September 2016
(Print All Articles)

HCV Guidance Panel Recommends Assessment for HBV Prior to Treatment

All patients beginning hepatitis C (HCV) treatment using direct acting antiviral (DAA) therapies should be assessed for hepatitis B (HBV), according the latest update from the American Association for the Study of Liver Diseases and Infectious Diseases Society of America Guidance Panel, which provides up-to-date guidance on the treatment of hepatitis C on its website, HCVguidelines.org

  
“Cases of HBV reactivation (an increase of the HBV virus) during or after DAA therapy for HCV have been reported in HBV/HCV co-infected patients who were not already on HBV suppressive therapy,” explains Raymond Chung, MD, co-chair of the HCV Guidance Panel. “The severity of these cases have ranged from mild to severe fulminant liver injury that can be life threatening. While we do not know how frequently this occurs, the Guidance Panel recommends HBV testing for all patients beginning DAA treatment for HCV.” 
 
Additionally, the Guidance Panel recommends:
  • HBV vaccination for all susceptible individuals (i.e., those not immunized or without evidence of response to immunization)
  • Obtaining a test for HBV DNA prior to DAA therapy in patients who could be actively replicating (i.e., those who are HBsAg positive)
  • Starting patients who meet criteria for treatment of active HBV infection on therapy at the same time — or before — HCV DAA therapy is started
  • Monitoring patients with low or undetectable HBV DNA levels at regular intervals (usually not more frequently than every four weeks) for HBV reactivation during treatments and placing those whose HBV DNA levels meet treatment criteria on HBV therapy as recommended by the AASLD’s HBV treatment guidelines
”While there currently isn’t enough data to make clear recommendations for patients who have been exposed to HBV and resolved the virus, whether spontaneous or after antiviral therapy, we recommend these patients be monitored for HBV reactivation,” says Susanna Naggie, MD, MHS, co-chair of the HCV Guidance Panel. “This is particularly important in the event of unexplained increases in liver enzymes and during and/or after completion of DAA therapy.”
 
Visit HCVguidelines.org for more information about these newest recommendations and to view other sections of the HCV Guidance.

FDA Issues Ban on Triclosan, CDC Continues to Provide Guidance Throughout Zika Outbreak

The Federal Drug Administration (FDA) issued its final ruling on Sept. 2 stating that certain consumer antiseptic wash products can no longer be marketed. The rule applies to 19 specific ingredients, including triclosan and triclocarban, and is specific to products that are intended for use with water and rinsed off after use. 

 
Triclosan and triclocarban, along with the other 17 common active ingredients that have been banned, did not demonstrate effectiveness over plain soap and are not safe for long-term daily use. 
 
The Centers for Disease Control and Prevention (CDC) updated its guidance for pregnant women and women of reproductive age regarding Zika virus transmission in Miami-Dade County, Florida. Transmission is no longer active in the Wynwood area of Miami; however, the active area of transmission has grown to 4.5 square miles from the original 1.5 square-mile area where Zika was first detected in Miami. 
 
You can get timely updates from FDA and CDC by subscribing to one of IDSA’s members-only email alert services. Content includes a range of topics, including drug warnings, recalls, and outbreak investigations. Recent alerts have included: 
 
Pregnant Women and Women of Reproductive Age for Zika Virus Infection Related to the Ongoing Investigation of Local Mosquito-borne Zika Virus Transmission in Miami-Dade County, Florida (CDC Alert, Sept. 20, 2016) 

FDA Issues Final Rule on Safety and Effectiveness of Antibacterial Soaps (FDA Alert, Sept. 2, 2016) 

FDA Advises Testing for Zika Virus in all Donated Blood and Blood Components in the US (FDA Alert, Aug.26, 2016) 

Update: Interim Guidance for the Evaluation and Management of Infants with Possible Congenital Zika Virus Infection (CDC Alert, Aug. 19, 2016) 
 
July 2016 Safety Labeling Changes Posting Includes 52 Products (FDA Alert, Aug. 15, 2016)

Medicare Will Soon Require More Coding Specificity on Claims

The "grace period” for ICD-10 coding is coming to an end. Starting Oct. 1, claims must be coded to the greatest specificity as supported by the documentation. 

 
Previously, the Centers for Medicare and Medicaid Services (CMS) had allowed for flexibility to make the transition to the ICD-10 code set easier for providers. CMS had said that claims would not be rejected by Medicare Administrative Contractors (MACs) as long the claim had a valid ICD-10 code from the correct “family of codes.” A “family of codes” is defined as those codes contained in a three digit set that are clinically related. For example, C81 designates Hodgkin’s lymphoma, but does not provide any more specificity as to the type of Hodgkin’s lymphoma. 
 
Beginning Oct. 1, 2016 claims with only three digit ICD-10 codes may be subject to denial and audit. Therefore in order to avoid payment delays, CMS recommends providers should code to accurately reflect the clinical documentation, and with as much specificity as possible. CMS also recommends providers should avoid using unspecified diagnosis codes when clinical documentation may support the use of a more detailed code. For example, ICD-10 code A40 indicates Streptococcal sepsis. However, if the clinical documentation supports the use of a more specified code, such as A40.3 – Sepsis due to Streptococcus pneumoniae, then the more specific code should be reported on the claim. 
 
For more information and provider resources, visit the ICD-10 CMS webpage: CMS ICD-10 Information.

Advocacy for New Antibiotics and Policies to Combat AMR Continues

In addition to the historic United Nations meeting this month, IDSA participated in numerous other meetings and events to advocate for sound public policy on antimicrobial resistance. 

 
Improving Regulatory Climate for Antibiotic R&D 

IDSA held a meeting with Janet Woodcock, Director of the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER), to discuss next steps for advancing policies to make it more feasible to conduct clinical trials for new antibiotics that address unmet medical needs. The meeting was a follow-up to an FDA workshop in July entitled: “Facilitating Antibacterial Drug Development for Patients with Unmet Need and Developing Antibacterial Drugs that Target a Single Species.” Discussion covered the scientific challenges pertaining to such development programs, including enrollment challenges, clinical trial designs and trial population. Also in September, the FDA, European Medicines Agency (EMA) and Pharmaceuticals and Medical Devices Agency-Japan (PMDA) issued a promising tripartite agreement regarding regulatory approaches for the evaluation of new antibiotics, which stressed the appropriateness of accepting greater degrees of uncertainty (i.e., smaller clinical trials) for new antibiotics that address an unmet need, the usefulness of other types of supplemental data in addition to clinical trials, and the importance of establishing clinical trials networks. 
 
IDSA Congressional Briefing 
 
IDSA co-hosted a congressional briefing in September with the Antimicrobials Working Group (AWG), a coalition of small pharmaceutical companies, to educate congressional staff about the need for new antibiotics, economic incentives, and feasible regulatory policies. IDSA board member Chip Chambers, MD, FIDSA, gave the clinician’s perspective on these issues, joining a panel featuring a sepsis patient, the CEO of Melinta Therapeutics, and an economist from the Duke-Margolis Center for Health Policy. 

Presidential Advisory Council Meeting 
 
The Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB) held a public meeting (PDF) also in September focused on antibiotic stewardship and infection prevention. IDSA Treasurer Helen Boucher, MD, FIDSA, and IDSA Diagnostics Task Force Chair Angela Caliendo, MD, FIDSA, serve on the PACCARB. The PACCARB, at the request of Health and Human Services Secretary Sylvia Burwell, will consider recommendations regarding prioritizing resources to combat antibiotic resistance. IDSA staff provided public comments at the meeting about the importance of a One Health multi-pronged approach to resistance that includes stewardship, infection control and prevention, surveillance and data collection, research, and innovation.

Helping Lawmakers Understand the Importance of LDTs and Risks of Proposed Regs

Proposed Food and Drug Administration (FDA) regulations on laboratory developed tests (LDTs) could have a disruptive impact on patient care and public health, and IDSA continues to educate policymakers about the important role of such tests and the potentially negative impact of the proposed regulations. 

 
The Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing on LDTs earlier this month. In advance of that hearing, IDSA Diagnostics Task Force (DTF) Chair Angela Caliendo, MD, FIDSA, briefed the committee on how ID physicians use LDTs and how proposed regulations could severely limit patient access to testing and thwart innovation. IDSA also submitted formal testimony (PDF) which furthered Dr. Caliendo’s points and offered alternative mechanisms for improving the oversight of LDTs while maintaining patient access to high quality testing and promoting innovation. The Senate HELP Committee Chairman, Senator Lamar Alexander (R-TN), quoted IDSA in his statement at the hearing. 
 
IDSA, the American College of Medical Genetics and Genomics, and the Association for Molecular Pathology hosted a congressional briefing the same day as the Senate hearing, featuring Dr. Caliendo and IDSA staff, to educate all congressional staff about LDTs and how they are used to guide effective patient care for a variety of diseases and conditions. IDSA and its partners also explained the consequences of proposed regulations that would limit the availability of some of these lifesaving tests. 
 
The Food and Drug Administration (FDA) will hold a meeting in early November of the Microbiology Devices Panel of the Medical Devices Advisory Committee, to discuss and make recommendations regarding risk classification of tests for transplant-associated opportunistic viral infections. Highest risk tests will likely be the first to undergo any new regulations, and IDSA is advocating that tests for transplant viruses be classified as moderate- as opposed to high-risk. IDSA has asserted that these tests have been in use for many years by clinical laboratories, with well-documented data demonstrating clinical validity and peer reviewed literature supporting their use. In many instances, these LDTs have become the standard of care. 
 
Congress and FDA continue to consider next steps on LDTs, such as revising and finalizing the draft FDA proposal, or crafting legislation to advance a different approach to LDT regulation, and IDSA will continue to be engaged.

Join HIVMA for Updates on the Ryan White Program at IDWeek 2016

If you’re a Ryan White provider, come join HIVMA from 12:15 to 1:45 p.m., Friday Oct. 28 at the Hilton New Orleans Riverside for the annual Ryan White Medical Providers Coalition luncheon. Catch up on the latest Ryan White news, network with other providers and share what's happening in your community. Email us to RSVP and for additional information.

AIDS, Global Antimicrobial Resistance, Zika: IDSA Global Health Covers the Latest

Report on 21st International AIDS Conference 

 
The 21st International AIDS Conference returned to Durban South Africa in July 2016 to recognize progress made in the 16 years since the world began to recognize the enormity of the global HIV crisis, but also to confront continuing challenges. In August, IDSA Center for Global Health Policy released AIDS 2016 Progress and Challenge (PDF), a report from the ground, summarizing the conference, and highlighting developments and challenges in HIV and tuberculosis research, treatment, prevention, and funding.
 
Global Antimicrobial Resistance—Solutions to a Worldwide Threat

Starting with the beginning of the antimicrobial age, when new medicines opened the era of modern medicine, through the peak years of new antibiotic drug development in the 1970s when physicians were said to have “an embarrassment of choices,” to the threats posed today, Global Antimicrobial Resistance (PDF), a new white paper released in advance of the United Nations high level meeting on antimicrobial resistance, tells the story of the issues and solutions to a worldwide threat.
 
Science Speaks Covers Zika Research and Funding Developments 
 
The Center for Global Health Policy’s Science Speaks blog followed policy makers and scientists responding to the spread of Zika and its impacts with posts on: 
 
An update to World Health Organization guidelines reflecting discoveries of how, and for how long after infection the virus may be transmitted sexually . . . while a bill to fund responses to the Zika outbreak stalled again in Congress. 
 
A study review confirming that Zika is a trigger for Guillain Barre Syndrome, and a cause of microcephaly and other neurological disorders. 
 
Concerns from medical provider organizations and agencies that lack of funding will stall new Zika responses.

OFID Podcast Explores Root Causes of Decline in ID Fellowship Applicants

A recent podcast in IDSA’s open access journal, Open Forum Infectious Diseases (OFID), features an interview with OFID Editor Paul Sax, MD, FIDSA and IDSA members Wendy Armstrong, MD, FIDSA, and Mike Edmond, MD, MPH discussing the challenges faced in strengthening the ID workforce. Dr. Armstrong is professor of medicine in the Division of Infectious Diseases at Emory University and chair of IDSA’s ID Recruitment Task Force. Dr. Edmond is clinical professor of Infectious Diseases and chief quality officer at the University of Iowa Hospitals and Clinics. 

 
Attend the IDWeek Town Hall: Securing the Future of ID to add your voice to the issues raised in the podcast and share your thoughts on addressing the challenges faced by the ID and HIV workforce. The Town Hall will be held Friday, October 28 from 6 to 7:30 pm in the New Orleans Theater. Visit http://www.idweek.org/townhall to submit a question or comment in advance.
 
   
Wendy Armstrong, MD, FIDSA  and Mike Edmond, MD, MPH

IDSA Education and Research Foundation: Steering Medical Students Toward ID

The IDSA Education and Research Foundation is pleased to announce that two recipients of the 2015 Medical Scholars Program scholarships have published research supported by their Foundation scholarships.  

 
Congratulations to Nathan Lo of Stanford University School of Medicine for publishing Evaluation of a Urine Pooling Strategy for the Rapid and Cost-Efficient Prevalence Classification of Schistosomiasis in PLOS Neglected Tropical Diseases and to Leila Kutob of the University of South Carolina School of Medicine for publishing Effectiveness of Oral Antibiotics for Definitive Therapy of Gram-negative Bloodstream Infections in the International Journal of Antimicrobial Agents
 
The Medical Scholars Program has supported hundreds of medical students with mentorship by IDSA and HIVMA members, giving the best and brightest in the field a first-hand look at the challenges and opportunities of working in infectious diseases. Through your support, the IDSA Foundation continues to provide opportunities for medical students. Consider making a donation today to support the 2017 Medical Scholars Program. Applications will be accepted starting early December.

Consumer Reports Publishes HIVMA’s Choosing Wisely Resource on CD4 Testing

Consumer Reports has released HIVMA’s first “Choosing Wisely” patient education resource, focused on helping patients understand when they need and don’t need CD4 testing. 

 
This resource is part of HVMA’s participation in the ABIM Foundation’s “Choosing Wisely” project, which aims to promote wise patient and provider decision-making about the most appropriate care based on a patients’ individual situation. The other four of HIVMA’s full set of five “Choosing Wisely” recommendations will also be featured in future Consumer Reports educational briefs.

Interested in Influenza Vaccine Delivery? Earn CMEs by Using a New Physician Resource from NFID and ICID

Seasonal influenza is a major global health concern, annually affecting one in six individuals in the U.S. More than 200,000 individuals are hospitalized, and 3,000–50,000 deaths occur each year due to influenza-related complications. Adults age 65 years and older are at higher risk of influenza complications. They are 10–30 times more likely to be hospitalized due to influenza-associated illness, and require longer hospital stays than younger adults. These effects are even more pronounced with increase in age. To promote, educate, and share information about the burden of seasonal influenza in the U.S., the National Foundation for Infectious Diseases (NFID), in partnership with the International Center for Infectious Diseases (ICID), and mdBriefCase Group Inc., developed a resource called the Influenza Knowledge Transfer Series. This complimentary educational activity was designed for healthcare professionals interested and involved in influenza vaccine delivery. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of NFID and ICID. NFID is accredited by the ACCME to provide continuing medical education for physicians. This free activity is accredited for 1.5 AMA PRA Category 1 Credits™. The activity includes two modules:

 
Module 1: Immunization challenges and options for vaccination strategies
Module 2: Case studies of a healthy 70-year-old female patient and a 79-year-old male patient with diabetes
 

In Memoriam: D.A. Henderson, MD, MPH

 
Donald “D.A.” Henderson, MD, MPH, FIDSA, longtime IDSA member, was a preeminent leader in the field of infectious disease, public health, and global health. He is most well-known for successfully leading the effort to eradicate smallpox. His contributions to the field of infectious diseases and to global health have saved tens of millions of lives, and smallpox remains the only human infectious disease to be entirely eradicated to date. 
 
Dr. Henderson was born in Lakewood, Ohio, and graduated from Oberlin College with a bachelor’s degree in chemistry. He went on to pursue his medical degree, which he received in 1954 from University of Rochester. He then joined the Epidemic Intelligence Service of the Communicable Disease Center, now the Centers for Disease Control and Prevention (CDC). In 1960, he received his masters of public health from Johns Hopkins University and became the chief of the virus surveillance section of the CDC. 
 
In 1966, Dr. Henderson became director of the 10-year campaign to eradicate smallpox, led by the World Health Organization (WHO) and profiled in the recent Microbe Hunters documentary series. By 1977, the last case of smallpox had occurred in Somalia, and the disease was declared eradicated. The success of the program paved the way for future vaccination and eradication efforts across the globe. 
 
“The effect that Dr. Henderson had on the field of infectious diseases as both a pioneer and a mentor cannot be understated,” said IDSA President Johan Bakken, MD, PhD, FIDSA. “His dedication to public health profoundly changed the trajectory of treating patients and preventing the spread of disease across the globe.” 
 
After working at WHO, Dr. Henderson became dean of the Johns Hopkins School of Public Health (now Johns Hopkins Bloomberg School of Public Health) and served in that role until 1990. Dr. Henderson served in the administrations of George H.W. Bush and Bill Clinton. He later founded the Johns Hopkins Center for Civilian Biodefense Strategies, now the UPMC Center for Health Security. 
 
He was the recipient of numerous prestigious awards including the National Medal of Science and the Presidential Medal of Freedom, the nation’s highest civilian honor. A long-time IDSA member, he presented the Smadel Lecture at the IDSA Annual Meeting in 2002, and he received IDSA’s Society Citation in 1996. In the early 2000s, he was a member of IDSA’s Bioterrorism Work Group, which developed resources for ID clinicians on smallpox and other pathogens that potentially could be used in bioterrorist events. His work with smallpox was unprecedented within the field of global health and remains as a model for disease surveillance and vaccination campaigns for vaccine-preventable illness throughout the world today. 
 
Dr. Henderson had a lasting impact on not only those who knew him personally, but all those familiar with his work to eradicate smallpox. 
 
“D.A. Henderson’s impact on global health is incalculable. Today, no one is faced with the threat of natural smallpox, the US is much more resilient to the threat of bioterrorism, and a large number of physicians and public health practitioners are more adept (including me) because of his mentorship and guidance. He was the commander-in-chief of infectious disease, and the entire world owes him a debt of gratitude,” states colleague and mentee of D.A. Henderson, Amesh Adalja, MD, FIDSA. 
 
Dr. Henderson is survived by his wife, Nana Bragg, his daughter, Leigh Henderson, and his two sons, David and Douglas Henderson.

In Memoriam: Lenae Fountain-Moss


Beloved member of the IDSA staff, Lenae Fountain-Moss, passed away July 9, 2016. Lenae had recently reached her 10-year anniversary with the Society, most recently in the role of receptionist and member of the Membership department. Many members will remember her kind and helpful manner on the phone as she greeted callers and assisted with questions regarding membership. Staff will miss her contagious and friendly energy and dedication to making the workplace a positive environment. She is survived by her daughter Iyana and granddaughter Alyssa.

In Memoriam: Leland F. Powers

Leland F. “Lee” Powers passed away on August 17, 2016. Lee was managing editor for The Journal of Infectious Diseases for over a decade after a previous long term at the journal Hospital Practice. Lee had a lasting impact on the journal and on those who knew him. “No one I know personified the term ‘gentleman’ more than Lee,” said JID Editor-in-Chief Martin S. Hirsch, MD, FIDSA. “He was a true professional at his work and a delightful human being.” 

 
Lee is survived by his wife, Carol; brother-in-law Charles Sexton and nephews Adam and Jared; sister-in-law and brother-in-law Ellen and Robert Meeropol; Carol's sons Alex, Michael and James and their families.

Member Report

Member Report

IDSA welcomes the following new members:

MEMBERS

Alam, Mohammad, MD

Angulo, David, MD

Apostol, Mirasol, MPH

Appleton, Melissa, MD

Atapattu, Dhammika, MD, PhD

Bacon, Oliver, MD, MPH

Badowski, Melissa, PharmD

Bhandari, Neetesh, DVM, PhD

Bock, Izona, MD

Brinkman, Mary Beth, PharmD, PhD

Calero Baquerizo, Fernando, MD

Caplan, Margaret, MD, MSc

Carroll, Heather, MSN

Chamie, Gabriel, MD, MPH

Choe, Ulyee, DO

Cohen, Ted, DPH, MD

Coles, Christian, MPH, PhD

Colley, Peter, PharmD

Cooper, Matthew, MBA, MD

Cowan, Raquel, MBBS

Davila, Samuel, MD

De Boer, Mark, MD, PhD

Demeter, Andrea, MD

Elshinawey, Rasha, PharmD

Fadul, Nada, MD

Gautam, Swapnil, MBBS, MD, MRCP

Goel, Chetan, MD

Good, Gary, MD

Hallur, Vinaykumar, MBBS, MD

Hammoud, Marwa, MD

Hanberger, Hakan, MD, PhD

Helou, Silvia, MD

Hernandez, Vata, PharmD

Houle, Claudia, MD

Huang, Angela, PharmD

Israel, Sarah, MD

Janelle, Jennifer, MD

Jayakumar, Rebecca, PharmD

Joel Chandranesan, Andrew Stevenson, MD

Kann, Dylan, MD

Ki, Moran, MD, PhD

Koren, David, PharmD

Lancki, Nicola, MPH

Langelier, Charles, MD, PhD

Lauriola, Marinella, MD

Love, Kari, CIC, MS, RN

Luchi, Michael, MD

Luedtke, Susanne, MD

MacDougall, Conan, MS, PharmD

Mathew, Annie, MD

Melnick, David, MD

Mitchell, Ardath, BSN, PharmD

Modjtabai, Khodadad, MD

Mueller, John, PhD

Nguyen, Lee, PharmD

Nguyen, Duc, MD, MPH, PhD

Oren, Noga, MD

Oude Lashof, Astrid, MD, PhD

Ozer, Egon, MD, PhD

Park, Michelle, PharmD

Patel, Twisha, PharmD

Patharkar, Mukul, MD

Patterson, Kristine, MD

Pinsky, Benjamin, MD, PhD

Poeschla, Eric, MD

Raghuram, Anupama, MD

Rizvi, Syed Irfan, MSc

Rodriguez, Carla, MPH, PhD

Rowland, Karen, MBBS

S, Divyashree, MBBS, MD

Saharia, Kapil, MD, MPH

Scheper, Henk, MD

Shafer, William, PhD

Shah, Kairav, MD

Shaikh, Gazala, MBBS, MD, MRCP

Sidney, David, MD

Slev, Patricia, PhD

Steinbrink, Julie, MD

Stevens, Anne, MD, MPH

Stock, Annie, PharmD

Suaya, Jose, MD, PhD

Sugimoto, Brent, MD, MPH

Taglietti, Marco, MD

Tompkins, Jason, MD, MPH

Townsend, Jennifer, MD

Trubiano, Jason, MBBS

Uhrig, Alexander, MD, PhD

Vaz, John, MBBS

Vyas, Nikunj, PharmD

Weld, Ethel, MD

Widmer, Kyle, MD

Wiedermann, Bernhard, MD

Wise, Gilbert, MD

Wiskirchen, Dora, PharmD

Wring, Steve, MSc, PhD

MEMBERS-IN-TRAINING

Abdelaal, Sameh, MBBS, MD

Abdelraouf, Kamilia, PhD

Abdoler, Emily, MD

Abul, Yasin, MD

Ackerley, Cassie, MD

Adachi, Kristina, MD

Adial, Ajay, MD

Agabawi, Salem, MD

Ahmad, Syed, MD

Ahuja, Monica, MD

Akinosoglou, Karolina, MD, PhD

Akselrod, Hana, MD, MPH

Al Balushi, Zakariya, MD

Al Hammoud, Roukaya, MD

Alaqili, Saba, DO

Aldrich, Aileen, MD

Ali, Maisa, MBBS

Almusa, Zainab, MBBS

Alvarado, Gadiel, DO

Anjum, Seher, MD

Artau, Annette, MD

Badawi Mohamed, Mohamed, MD

Baneman, Emily, MD

Bansal, Nitin, MBBS, MD

Barrett, Jessica, DO

Beaird, Omer, MD

Becker, Dawn, MD

Ben-Aderet, Michael, MD

Benjamin, Carla, MBBS

Blair, Paul, MD, MSPH

Bluen, Benjamin, MD

Boguniewicz, Juri, MD

Bohan, Jefferson, PharmD

Bourgi, Kassem, MD

Briggs, Jessica, MD

Bryson-Cahn, Chloe, MD

Burns, Julianne, MD

Bystritsky, Rachel, MD

Casto, Amanda, MD

Chanderraj, Rishi, MD

Chang, Chris, DTM&H, MA, MBBS, MRCP

Chang, Amy, MD, PharmD

Chao, Andrew, MD

Chen, Li-Chien, DO

Chew, Christopher, BCh, DTM&H, MB

Chiang, Angela, MD

Cho, Yoshiaki, MD

Cloke, Christina, MD

Cohen, Gabriel, MD

Conserve, Donaldson, PhD

Cushman, Teresa, MD

Dasgupta-Tsinikas, Shom, MD

Data, Rupak, MD, PhD

de Gijsel, David, MD

Deering, Caytlin, DO

Desai, Alpa, MD

Dillon, Rhonda, MD, MPH

Dobrzyznski, David, MD

Dougherty, David, MD

Dousa, Khalid, MBBS

Drelick, Alexander, MD

Dretler, Alexandra, MD

Dutcher, Lauren, MD

Eickhoff, Christa, MD

El helou, Guy, MD

Elabor, Abdulrahman, MD

Eldos, Batool, MD

Elhenghari, Emad, BCh

Elmaki, Nada, MBBS

Endres, Bradley, PhD

Enser, James, MD

Ewers, Evan, MD, MS

Farran, Sumaya, MD

Fleece, Molly, MD

Friel, Brian, MD

Fung, Monica, MD, MPH

Gaikwad, Rahul, MD

Gallegos, Cinthia, MD

Galloza-Rivera, Suhein, MD

Gangat, M. Azhar, MD

Garcia-Maurino, Cristina, MD

Gass, Jason, DO

Gavigan, Patrick, MD

Gern, Benjamin, MD

Gill, Harmeet, MD

Gilliams, Elizabeth, MD, MS

Glaser, Allison, MD

Goodman, David, MD, MS

Govind, Anusha, MD

Go-Wheeler, Marianne, MD

Gray, Megan, MD

Gulleen, Elizabeth, MD

Ha, Lawrence, MD

Ha, Karen, MD

Hahn, Andrea, MD

Hall, Toni, DO, MD

Harris, Che, MD

Hayes, Justin, MD

Hazra, Aniruddha, MD

Heintz, Eric, MD

Hicks, Courtney, MD

Hlatshwayo, Matifadza, MD, MPH

Huang, Felicia, MD

Huang, Tian, MD

Husain, Ahmed, MD

Ingnam, Sisham, MBBS

Iqbal, Fatima, PharmD

Ishioka, Haruhiko, MD

Jacob, Paul, MD, MPH

Jimada, Ismail, MD

Kapinos, Piotr, MD

Kassar, Rawan, MD

Kaur, Amrit, MD

Keighley, Caitlin, MD

Kershaw, Colleen, MD

Keyser, Roberta, MD

Khalid, Khadieja, BCh, MB

Khalil, Sarwat, MBBS

Khan, Saahir, MD, PhD

Khan, Imran, MD

Khoo, Teresa, MD

Khouzam, Nour, MD

Kim, Ji-Yeon, MD

Kosek, Margaret, MD

Krolikowski, Matthew, DO

Kulkarni, Prathit, MD

Kuntz, Katharine, MD

Kuriakose, Kevin, MD

Kuvhenguhwa, Maita, MD

LaFortune, Alexander, MD

Lam, Paul, MD

Lam, Philip, MD

Lamb, Gabriella, MD

LaNasa, Rachel, MD

Langeveld, Tessa, MD

Larson, Derek, DO

Laurent-Rolle, Maudry, MD, PhD

LaVergne, Stephanie, MD

LaVie, Katherine, MD

Lee, Ji Hye, MD

Lerner, Andrea, MD

Lewis, Julia, DO

Li, Sui Kwong, MD

Liu, Sean, MD, PhD

Lother, Sylvain, MD

Luther, Megan, PharmD

Mada, Pradeep, MD

Majeed, Aneela, MD

Majeed, Nadia, MD

Manzoor, Khalid, MBBS

Markwell, Poppy, MD, MPH, MSPH

Marr, Candace, DO

Marty Vigo, Harry, MD

Maughan, Ashly, MD

McBride, Darrell, DO

McConeghy, Kevin, MD

McConville, Thomas, MD

McDonald, Philip, MD

McKenna, Megan, MD

McKittrick, Noah, MD

McPherson, Tristan, MD

Medrzycki, Magdalena, PhD

Meisner, Jessica, MD, MS

Mishkin, Aaron, MD, MS

Monogue, Marguerite, PharmD

Mosser, Jonathan, MD, MPH

Mudassar, Qurat Ul Ain, MD

Mukaigawara, Mitsuru, MD

Mukka, Mallikarjuna, MD

Nagori, Maria, MD

Nahar, Julie, MD

Nanayakkara, Deepa, MD, MS

Narayan, Muthu, DO, MPH

Navarro, Virginia, MD

Nguyen, Trong Tien, MD

Niknam, Negin, MD

Nowbakht, Cima, DO

Nyemba, Vimbai, MD

O'Brien, Brigid, MD

Ochoa, Aaron, MD

Odili, Ogheneruona, MD

OKoye, Stella, MD

Olson, Erika, DO

Oni, Ibukunolupo, MD

Onufrak, Nikolas, PharmD

Onuorah, Luke, MBBS, MPH

Oring, Justin, DO

Pagkas-Bather, Jade, MD

Panesso-Gomez, Santiago, MD

Parakadavathu, Rakesh, MD

Parke, Cade, DO

Pascual, Arturo, MD

Patel, Mehul Kumar, MD

Patil, Pratik, MBBS, MD

Pellegrini, Daniela, MD

Pepe, Dana, MD, MPH

Pereira Rodrigues, Otavio, MD

Persichino, Jon, DO

Peterson, Nathan, PharmD

Philip, Nirmol Pearl, MD

Powell, Kelsey, PharmD

Prayag, Parikshit, MD

Pritchard, Haley, MD, MS

Pullen, Matthew, MD

Ramakrishnan, Balavinoth, MBBS, MD

Rasool, Altaf, MD

Raza, Ambreen, MD

Richards, Rocco, MD

Richardson, Katherine, MD

Rittmann, Barry, MD

Robinson, Matthew, MD

Salahudeen, Luqman, MD

Sanchez, Amaury, MD

Santevecchi, Barbara, PharmD, RPh

Sayeed, Muneeba, MBBS

Schnee, Amanda, MD

Schneider, Jack, MD

Schubert, Beke, MD

Scott, Janet, BCh, MB, MRCP

Scully, Morgan, MD

Seidelman, Jessica, MD

Serrano, Ruth, MD

Seshadri, Pratibha, MD

Shaban, Ameerah, MD

Shah, Melisa, MD

Shay, Emily, MD

Shiferaw, Bethel, MD

Shimizu, Akihiko, MD

Siblisa, Kedesha, MD

Silvaggio, Jessica, MPH

Sirdar, Nadia, MD, MPH

Small-Saunders, Jennifer, MD

Smith, Mallory, MD

Spicer, Jennifer, MD

Spinelli, Matthew, MD

Stawarz, Kimberly, MD

Sternlieb, Mitchell, MD

Stohs, Erica, MD, MPH

Story-Roller, Elizabeth, MD

Strand, Andrew, MD

Sukhwani, Kalpesh, MD

Summers, Nathan, MD

Sun, Jonathan, DO

Tallman, Gregory, PharmD

Tan, Eugene, MD

Tanpaibule, Tananun, MD

Tanveer, Farah, MD

Teale, Alastair, MD

Tellez Watson, Patricia, MD

Thien, Siew Yee, MD

Thompson, Andrew, MD

Timbrook, Tristan, PharmD

Tolentino, Bryan, MD

Tomatis Souverbielle, Cristina, MD

Turner, Orlando, MD

Ulloa, Erlinda, MD

Varghese, Merin, MD

Vendrame, Elena, MD

Visuttichaikit, Suttichai, MD

Vogt, Matthew, MD, PhD

Vyas, Kapil, DO

Waddell, Joel, DO

Webb, Camille, MD

Wiggers, Brad, MD

Wilbur, Christopher, MD

Williams, Janna, MD

Williams, Eloise, MPH

Wilson, Jessie, MD

Wilson, Rosemary, MSN, NP

Wondyrad, Seblewongel, MD

Wood, Shannon, MD, MPH

Wood, Stuart, MD

Workneh, Meklit, MD, MPA

Wright, Theodore, MD

Yalamanchili, Harika, DO

Yaratha, Gokul, MD

Yazak, JoMarie, RPh

Yepez Guevara, Eduardo, MD

Zakrzewski, Jan, MD

Zuberi, Ayesha, MD

RESIDENTS

Abel, Mark, BCh, MB

Adelman, Max, MD, MSc

Afghan, Abaseen, MD

Al Sidairi, Hilal, MD

Alkhathlan, Ahmed, MBBS

Alvarez, Barbara, MD

Barnes, Aaron, MD, PhD

Benjamin, Jackie, PharmD

Best, Michael, MD, MPH

Bogler, Yael, MD

Bogorodskaya, Milana, MD

Brotherton, Amy, MD

Carpenter, Kelly, MD

Catala, Jaime, MD

Cebula, Brennan, MD

Chakrabarty, Melony, MD

Chamberlain, Nicholas, MD

Chawla, Karishma, MD

Cherabie, Joseph, MD

Chin, Larissa, MBA, PharmD

Cifuentes, Angelica, MD

Cook, Gregory, PharmD

Corcorran, Maria, MD

Correa, Jesmarie, MD

Craft, Rachael, PharmD

Cueva, Carlos, MD

Cumagun, Pia Marie, MD

Debroy, Paula, MD

Delaney, Daniel, PharmD

Delgado, Miluska, BCh

DiBartolomeo, Christina, MD

Dietrich, Tyson, PharmD

Dizon, Erin, MD

Do, Michelle, PharmD

Donald, Bryan, PharmD

Dufour, Kevin, MD

Escobar, Daniel, MD, MSc

Farley, Joshua, MD

Favela, Emanuel, MD

Fedewa, Marie, DO

Ferren, Ryan, PharmD

Findlater, Aidan, MD, MSc

Fletcher DePree, Robin, MD

Foppiano Palacios, Carlo, MA, MD

Fox, Teresa, MD

Francisco, Denise Marie, MD

Friedman, Daniel, MD

Gaglani, Bhavita, MD

Ghaith, Jenan, BCh, MBBS

Ghorbandi, Abdul, MBA, PharmD

Gobeille Paré, Sarah, MD

Greenfield, Katharine, MD

Grome, Heather, MD

Groover, Troy, MD

Gupta, Alok, MD

Guzman, Janitzio, MD

Hayfron, Kweku, MD, MS

Herigon, Joshua, MD, MPH

Hersey, Roby, PharmD

Hoffmann, Wes, PharmD

Hogan, Catherine, MD

Huggins, Joanthan, MD

Huynh, Trinh, PharmD

Hysell, Kristen, MD

Jakubowski, Robert, MD

Jimenez, Xavier, MD

Khaddam, Sinan, MD

Kifer, Brionna, DO

Kim, Jae, MD

Klein, Adam, DO

Kobic, Emir, PharmD

Kolli, Eiswarya, MD

Konold, Victoria, MD

Kouba, Sammantha, DO

Kufel, Wesley, PharmD

Laflamme, Jérôme, MD

Lau, Jennifer, MD

Lazo, Alex, MD

Liu, Amy, MD

Lopez - Romo, Alicia, MD

Lorio, Marco, MD

Love, Kelsey, PharmD

Lowry, Michael, MD

Ma, Jimmy, MD

McCreary, Erin, PharmD, RPh

Medina, Rita, MD

Merchant, Elisabeth, MD

Morrison, Lindsay, MD

Murillo, Juan Carlos, MD

Mushtaq, Kamran, MBBS

Naeem, Doaa, PharmD

Nunley, Loren, MBA, MD

Ocheretyaner, Eric, PharmD

Oikonomou, Katerina, MD, PhD

Osman, Majdi, DTM&H, MBBS, MPH, MRCP

Parra, Yury, MD

Pearson, Jeffrey, PharmD, RPh

Powers, Harry, MD

Quintero, Orlando, MD

Rac, Hana, PharmD

Rahama, Omar, MD

Rajasekaran, Arun, MBBS

Ramsey, Andrea, MD

Razaki, Hamid, PharmD

Reap, Leo, DO

Rearigh, Lindsey, MD

Requena Penenori, Jorge, MD

Reyes, Cristina, PharmD

Robinson, Evan, MD

Sann, Khine, MD

Sansom, Sarah, MD

Sasaki, Toshiharu, MD

Sears, William, MD

Seddon, Megan, PharmD

Seiler, Garret, DO

Selent, Cameron, MD

Sfeir, Maroun, MD, MPH

Shafiee, Hasan, MD

Shams, Madeeha, MBBS, MS

Shastri, Bhagyashree, MD

Sherman, Amy, MD

Singh, Karandeep, MD

Skipper, Caleb, MD

Snitchler, Christopher, MD

Solasaari, Terhi, MD

Steiner, Kevin, MD, PhD

Stewart, Cassie, PharmD

Stubbins, Ryan, MD

Tahir, Madiha, MD

Taves, Woody, MD

Thompson, Michael, DO

Thompson, Chad, MD, MT(ASCP)

Tidwell, Ansley, PharmD

Tirmizi, Samad, MD

Visweshwar, Haresh, MD

Vocelka, Lucas, DO, MA

Volpe, Peter, MD

Vu, Betty, MD

Wang, Tina, MD

Wang, Nan, PharmD

Weaver, Christian, MD

Welford, Elliott, MD

Yokoyama, Shuhei, MD

Zamora, Danniel, MD

Zarraga, Christopher, MD

Zhou, Shiwei, MD

STUDENTS

Abu ESBA, Laila Carolina

Agarwal, Saroochi

Aggarwal, Sahil

Albritton, Hannah

Alghamdi, Wael

Ali, Shawkat

Anderson, Thomas

Arboleda, Alejandro

Bachman, Victoria

Baker, Sarah

Beeson, Amy

Bianchini, Monica

Blaskewicz, Caitlin

Bohlega, Mohamed

Bouzigard, Rory

Brombach, Meghan

Centeno, Mary Grace

Chandramouli, Shruti

Chao, Joshua

Chiasson, Jordan

Clement, Danielle

Comstock, David

Counts, Christopher

Darvic, Patric

Das, Sibani

D'Couto, Helen

Dearing, Heather

D'Mello, Rahul

Everett, Hayley

Feister, John

Ferrin, Bree

Fetters, Kirk

Fried, Nicholas

Gardner, Julianna

Gergen, Daniel

Gomez, Sara

Gootenberg, David

Gramatniece, Alise

Grewal, Udhayvir

Gu, Mofan

Guerra, Francisco

Hagan, Caroline

Haller, Blake

Han, Paul

Hanslits, Katherine

Hareza, Dariusz

Harrison, Holly

Hickey, Andrew

Hoffmann, Joseph

Hunter, Tammy

Ito, Andrea

Iyengar, Siddharth

Kaplan, Tessa

Kardux, Mitchell

Kumar, Shweta

Kushner, Lauren

Ladzekpo, Deawodi

Lara, Jose Ramon

Lee, Frances

Li, David

Li, Xuan

Ligon, Marianne

Ma, Lucy

Maldonado, Lauren

Marolf, Cole

McCoy, Molly

McGrady, Tyler

Medwick, Allan

Mohan, Charan

Monnig, Louis

Murrill, Matthew

Nebeluk, Nazary

Nguyen, Don

Nguyen, Andrew

Nielsen, Travis

Nisenbaum, Luba

Nowicki, Diana

Osborn, Rebecca

Ozog, Stosh

Pack, Christine

Palmer, Stephanie

Panford, Felix

Pham, Nathan

Pietz, Harlan

Rolim, Daniel

Saxena, Shikha

Schiff, Abigail

Shanmuga Kani, Rathina Kumar

Shillingford, Kelissa

Silva, Julia

Singh, Lovepreet

Singh, Kanal

Smith, Jake

Soo, Jeremy

St Martin, Brad

Stav, Jordan

Stephens, Nicole

Uh, Eugene

Vanchiere, Catherine

Wagner, Kaitlin

Walker, Bryan

Waller, Derrick

Wang, Yihui

Wesevich, Austin

Wu, Shaohan

Yates, Thomas

Yuh, Bianca

Zon, Rebecca

ASSOCIATES

Abwa, Terumbur

Acosta, Jennifer

Arhin, Francis

Aslanian, Meghan, PharmD

Beasley, Joshua, PA-C

Belley, Adam, PhD

Bennett, Sean, MD, PhD

Bergevin, Marco, MD

Bistrica, Caitlin

Cady, Beth, PharmD

Cannon, Lovick, PhD

Cavanaugh, Catherine, DO

Chu, Chau, PharmD

Cordero, Sabrina, BSN, FNP, MSN

Crandall, Hillary, MD, PhD

Cruz, Roma, MD

de Leseleuc, Louis, PhD

DeCamillis, Rebekah

Eremin, Sergey, MD, PhD

Garrity-Ryan, Lynne

Gibble, Allison, PharmD

Gimenez-Sanchez, Francisco

Griffith, Steven, PhD

Guirguis, Micheal, PhD

Hagan, Stephanie, PharmD

Haj, Reem, PharmD

Hasan, Nur

Heslin, Jacqueline, BSN, RN

Heyob, Shirley, PharmD

Jeon, Eun

Kincaid, Scott, PharmD

King, Madeline, PharmD

Kleinpeter, Myra, MD, MPH

Le, Kenneth, PharmD

LeBlanc, Jason, PhD

LeCompte, Brandi, NP

Lee, Colin, MSc, PharmD

Lucas, Jaclyn, PA-C

Matten, Jens

McCrory, Kim, PharmD

McGregor, Jennifer, RPh

Monnig, Louis

Olans, Rita, NP

Oraby, Sherief, BCh

Papathanasiou, Nikolaos, MD

Persad-Clem, Reema, ScD

Politis, Paula, PharmD

Reimer, Melissa, MD

Resurreccion Delgado, Cristhian, BCh, MD

Rolek, Kiri, PharmD

Rosato, Adriana, PhD

Salib, Iriny, PharmD

Siegert, Sherry, PharmD

Steenbergen, Judith

Steenhoek, Melissa, PharmD

Sweeney, Kimberly, PharmD

Teneyck, Carol, MSN

Toia, Jacquie, NP

Valvo, Bee

Van Epps, Puja, MD

Weinstock, Clara

Whitfield, Natalie, PhD

Williams, Calvin, MD, PhD

Wyckoff, Kevin, MSc

Zanewicz, James, JD

Be Part of the Solution at IDWeek Town Hall

Be Part of the Solution at IDWeek Town Hall! You don’t want to miss this unprecedented opportunity to engage in a lively discussion about the future of ID. In place of the traditional business meetings held at IDWeek, IDSA and HIVMA will host the first-ever town hall style meeting where we will share with you the work we are doing to address concerns over compensation and the decline in ID fellowship applicants. Lend your voice and take part in the solution to securing the future of this field.

We have begun the countdown to IDWeek 2016. In one month, over 6,500 ID professionals will be gathered in New Orleans to share and engage in the latest developments in the field of infectious diseases. Repeatedly, we are told that one of the aspects our members value the most about IDWeek is the opportunity to network with their peers. This year, for the first time, IDSA and HIVMA will be hosting a Town Hall event specifically designed to foster networking and open a dialogue with our members. 

 
IDWeek 2016 Town Hall: Securing the Future of ID, which will replace the annual business meeting typically held during the conference, will be held on Friday, October 28 from 6 – 7:30 PM in the New Orleans Theater of the convention center. We will discuss how the ID community can work collaboratively to ensure a robust ID and HIV workforce for the future. HIVMA’s chair, Carlos del Rio, and I will co-chair the event, and we will hear from Wendy Armstrong, chair of the IDSA ID Recruitment Task Force, who will provide updates on our efforts to address the decline in ID fellowship applicants, and Dan McQuillen, chair of the IDWeek Program Committee, who will review potential strategies to improve compensation and discuss other concerns that are facing our specialty. The heart of the event will focus on listening to you—taking your questions, listening to the concerns you face in your career as an ID physician, and hearing your thoughts on possible solutions. 
 
In advance of the Town Hall, I encourage you to visit the Town Hall webpage and submit your questions or concerns that you would like to have discussed during the meeting. Members will also have an opportunity to ask questions in person. We are anticipating a lively and productive conversation. Please also check out the IDSA website to see what IDSA is doing to promote the ID specialty and learn how you can become part of the solution. 
 
The Town Hall will be just the beginning of what we hope will be an ongoing dialogue with members on these critical issues facing our specialty. I’m excited to announce that today IDSA has launched a members-only online community called MyIDSA. This is a community specifically designed to encourage collaboration among our members. 
 
I hope that you will find MyIDSA to be the perfect format for posting questions and sharing resources and ideas with your colleagues in the discussion board section called “IDea Exchange." MyIDSA will allow you to search for members, post to and browse the resource library, find news clips, and read about the latest news in our field. We expect that the discussion generated at the Town Hall will continue on MyIDSA, but the possibilities for future topics to be covered are endless—MyIDSA is your community, your access to the 10,000+ members of our Society. 
 
Help us shape the future of ID! Please join me and participate in both of these exciting new ventures. Your thoughts and input are essential to the direction of our Society and to the success of the field of ID. We are waiting to hear from you.

IDSA’s Long-Standing Priorities Reflected in UN Declaration for Fighting AMR

IDSA was one of the first voices to call for a comprehensive response to antimicrobial resistance over a decade ago. Last week’s UN General Assembly meeting on AMR and subsequent declaration were important steps towards galvanizing worldwide leadership and collaboration on the development and implementation of national and global action plans to address this grave global public health crisis. IDSA Vice President Paul Auerwarter, MD, MBA, FIDSA and Treasurer Helen Boucher, MD, FIDSA were among the attendees at the UN meeting.

In a historic meeting this month, the United Nation’s General Assembly declared a commitment to fight antimicrobial resistance (AMR) by developing a strategy to prevent infections, protect existing drugs through stewardship, expand surveillance, and encourage the research and development of much-needed new antimicrobials, diagnostics and vaccines—adopting many of IDSA’s key recommendations.  

 
The meeting marked only the fourth time in the UN’s history that the body addressed a health issue, signaling that AMR has reached a level of significant concern worldwide. IDSA Vice President Paul Auwaerter, MD, MBA, FIDSA, and Treasurer Helen Boucher, MD, FIDSA, were among the world leaders in attendance. The meeting is an essential step towards galvanizing worldwide leadership and collaboration on the development and implementation of national and global action plans to address this grave global public health crisis. With the participation of IDSA leaders, the United Nations recognized the particular threat of increasing resistance to antimicrobial drugs, and issued a call for the mobilization of investments for research and development on new antimicrobial medicines, diagnostics, and vaccines. The inclusion of a call for innovative financing and investment mechanisms that ensure a public return on investment, resources for strengthened infrastructures to monitor and manage antibiotic use and resistance patterns, and educational and awareness campaigns for the public and all health care professionals to ensure access to and the optimal use of antimicrobial medicines, are an indication that this first step will be followed by many more initiatives. 
 
IDSA was one of the first voices to call for a comprehensive response to antimicrobial resistance over a decade ago. Prior to the General Assembly meeting, IDSA was among a select group invited to present to the UN to help shape the organization’s consideration of this important issue. IDSA’s recommendations included calling upon all of the member nations to commit to a robust response to AMR including:
  • antimicrobial stewardship; 
  • incentives for research and development of new antibiotics and diagnostic tests;
  • infection prevention and control;
  • surveillance and data collection;
  • research to better understand resistance and the impact of our interventions; and 
  • investment in the infectious diseases, health care and public health workforce.  
In advance of the UN meeting, IDSA circulated a public petition in support of coordinated global action to address AMR, which was signed by more than 2,000 people across the world. 
 
On the eve of the General Assembly, IDSA co-hosted along with the Center for Disease Dynamics, Economics and Policy (CDDEP) a Forum on Sustainable Access to Effective Antibiotics. The event brought together an international group of experts to discuss stewardship, conservation, innovation and global accountability and governance. 
 
IDSA will remain a strong partner with global health leaders to ensure initial and continued progress on the critical steps outlined in the declaration.
 
 

Countdown to IDWeek 2016

IDWeek 2016 is just one month away. Here are a few resources and events you won’t want to miss. Come match your knowledge of ID trivia with contestants from three New Orleans ID programs at the IDWeek Bug Bowl! This year’s meeting features nine accredited satellite symposia. The Opening Reception and Posters in the Park are always a big draw and the IDWeek Town Hall will be the event everyone is talking about! Start planning your week now!

IDWeek 2016 is just a month away and below are just a few highlights of resources, sessions and events you won’t want to miss. For all of the most up-to-date information and to register, go to www.idweek.org

 
Abstracts 
 
Abstracts will be available through the Interactive Program planner and the IDWeek Mobile App. Abstracts will also be published in a special online supplement to Open Forum Infectious Diseases (OFID), the open access journal from IDSA and HIVMA. 
 
Opening Reception and Posters in the Park 
 
Be sure to attend the Opening Reception and Posters in the Park, Wednesday, Oct. 26 in the Poster Hall, 6 – 7:30 p.m. The wine and cheese reception will feature poster presentations from medical students, residents and fellows that have been specially selected by the respective societies. 
 
Town Hall: Securing the Future of ID  
 
Be part of the solution! Attend this special Town Hall meeting, Friday, Oct. 28, at 6 p.m. in the New Orleans Theater, to learn about efforts by IDSA and HIVMA to address ID and HIV workforce challenges. Held in lieu of the traditional IDSA and HIVMA Business Meetings, the Town Hall will be an interactive forum where members can contribute their ideas and voice their concerns. 
 
IDBugBowl 2016 
 
Come match your knowledge of ID trivia with contestants from three New Orleans ID programs! The teams will battle it out to see who comes out on top in the inaugural IDBugBowl. This fun session—which is geared specifically for fellows, residents, and medical students—takes place Saturday, Oct. 29, 10:30 a.m. – noon in Theater C.
 
Satellite Symposia 
 
IDWeek 2016 will play host to a number of affiliated events in New Orleans, including nine accredited satellite symposia that offer CME that is supplemental to credits offered by the official IDWeek program. The IDExpo Hall will also feature a Learning Lounge for attendees to view 45-minute presentations from various exhibiting companies during exhibition hours (10 a.m. – 2 p.m., Thursday-Saturday). Further details for these and all affiliated events will be available in October at www.idweek.org
 
 MOC Pilot at IDWeek 2016  
 
In addition to CME and CPE credit, IDWeek attendees can now earn up to 18.25 maintenance of certification (MOC) points for selected interactive sessions at IDWeek. Download the meeting app to participate in the sessions. Following the sessions, visit the CME/CPE/MOC pavilion or go online after the meeting to complete an evaluation, which requires your American Board of Internal Medicine (ABIM) number and date of birth. IDSA will report your MOC points to ABIM within one week of the conclusion of IDWeek. Visit the IDWeek website for the list of sessions, the Interactive Program planner and the meeting app for session details, and look for the CME/MOC logo next to session titles in the Final Program book. 
 
Additional MOC points can be earned through participating in pre-meeting workshops, which include the updated Hepatitis C MOC module, along with the Vaccines 2015 and Travel/Tropical Medicine 2015 MOC modules. 
 
Register now to take advantage of the best travel rates. Information about housing and travel discounts can be found at http://www.idweek.org/attendees/housing-and-travel/.

Journal Club

Five Days of Antibiotics for Community-Acquired Pneumonia: Good Enough? BDG Serum Testing and Invasive Fungal Infections in Stem Cell Transplant Patients; Zero HIV Transmissions with a Suppressed Viral Load: Is the Risk Zero? Procalcitonin-Guided Therapy in Critically Ill Patients

In this feature, a panel of IDSA members identifies and critiques important new studies in the current literature that have a significant impact on the practice of infectious diseases medicine.

Click here for the previous edition of Journal Club. For a review of other recent research in the infectious diseases literature, see “In the Literature,” by Stanley Deresinski, MD, in each issue of Clinical Infectious Diseases.
Back to Top 
 Five Days of Antibiotics for Community-Acquired Pneumonia: Good Enough?
Reviewed by Christopher J. Graber, MD, MPH, FIDSA 

The 2007 guidelines for management of community-acquired pneumonia (CAP) endorsed by IDSA and the American Thoracic Society recommend a “minimum” of five days of antibiotic therapy for CAP and that patients must meet clinical stability criteria (afebrile for at least 48 hours, stable vital signs) for antibiotics to be discontinued. A recent study published in JAMA Internal Medicine evaluated whether five days of therapy is indeed sufficient for patients meeting clinical stability criteria.

In the study, 312 patients hospitalized for CAP in four teaching hospitals in Spain were randomized to either have antibiotic therapy stopped at five days if clinical stability criteria were met or to have their antibiotics continued for longer at the discretion of their treating physicians. Patients who were immunosuppressed, had health care exposure within 14 days, received antibiotics within 30 days, or were admitted to the intensive care unit were excluded. Forty percent of patients had Pneumonia Severity Index (PSI) scores of IV or greater; 80 percent were treated with fluoroquinolones.

In the intervention arm, 162 patients received a median of five days of therapy (interquartile range [IQR] 5-6.5); 150 patients in the control arm received a median of 10 days (IQR 10-11). In the intention-to-treat analysis, clinical success was similar in both arms at day 10 (56.3 percent vs. 48.6 percent) and day 30 (91.9 percent vs. 88.6 percent), as was improvement in CAP symptom questionnaire scores at day 10. Among patients with PSI scores of IV and greater, clinical success at day 30 was significantly higher in the intervention arm (93.1 percent vs. 80.3 percent, p=0.04). In the per-protocol analysis, readmission at 30 days was lower in the intervention arm (1.4 percent vs. 6.6 percent). 

This study adds to a slowly enlarging group of studies across many common infectious conditions that show, when compared to longer courses, shorter courses of antibiotic therapy are typically at least equivalent. It provides strong impetus for antimicrobial stewardship initiatives to reduce duration of therapy for CAP to five days for patients meeting clinical stability criteria.

(Uranga et al. JAMA Intern Med. 2016;176(9):1257-1265.)

 
Back to Top
BDG Serum Testing and Invasive Fungal Infections in Stem Cell Transplant Patients
Reviewed by Erica Kaufman West, MD

Patients receiving both allogeneic and autologous hematopoietic stem cell transplantation (HSCT) are at high risk for invasive fungal infections (IFI). (1 -> 3)-β-D-glucan (BDG) is a polysaccharide cell wall component found in most pathogenic fungal species, such as Aspergillus, Candida, Pneumocystis, and Fusarium. A single-center study recently published in Transplant Infectious Disease looked at HSCT recipients (current or within the last year) and followed BDG twice weekly until resolution of risk factors for developing an IFI. 

The early phase was determined to start at the beginning of myeloablative therapy up to 30 days after HSCT. Late phase was defined as >30 days but <1 year after HSCT. The Fungitell® assay was used, with positive results noted at ≥80 pg/mL. Samples were classified as “no evidence” for IFI or “possible,” “probable,” or “proven” IFI based on the definitions provided by the European Organization for Research and Treatment of Cancer Invasive Fungal Infections Cooperative Group and the Mycoses Group.  

The researchers obtained 308 samples from 45 patients, with about 75 percent drawn in the early phase. Most patients (73 percent) were allogeneic HSCT patients. Notably, almost all (78.6 percent) were on anti-fungal prophylaxis (medication not specified). Only 16 samples were obtained during a “possible” or “probable” IFI, and these had significantly higher BDG levels than those with “no evidence” (median 170 pg/mL vs. 15.4 pg/mL, p<0.001). They found the sensitivity of “possible” or “probable” IFI was 81 percent, specificity was 98 percent, negative predictive value (NPV) was 99 percent, and positive predictive value was 65 percent. 

From this study, BDG has an excellent NPV (>99 percent) and thus is a helpful tool in ruling out IFI in adult HSCT patients. This is a good “real-world” study where patients were likely taking medications noted to give false positive BDG results, making the high NPV worth noting. In addition, almost all of the patients were on antifungal prophylaxis, which has been shown to decrease sensitivity. This study provides some evidence that BDG is a reliable test for ruling out IFI in the adult HSCT population, which can prove helpful in avoiding empiric antifungal therapy.

(Reischies et al. Transpl Infect Dis. 2016;18:466-470.)

 
Back to Top
Zero HIV Transmissions with a Suppressed Viral Load: Is the Risk Zero?
Reviewed by Brian R. Wood, MD

The true risk of HIV transmission from an infected partner with routinely suppressed HIV RNA level on antiretroviral therapy (ART) to an uninfected partner remains unknown. The topic is highly clinically relevant because it affects counseling for serodifferent partners, particularly when considering pre-exposure prophylaxis, conception options, and other factors. The PARTNER study, recently published in JAMA, provides compelling evidence, but some questions linger.

In this prospective, multinational European investigation, researchers enrolled serodifferent adult couples (61.7 percent heterosexual, 38.3 percent men who have sex with men [MSM]) in which the HIV-infected partner had a suppressed viral load on ART; all couples reported condomless sex (for a median 2 years prior to enrollment). Overall, 1,166 couples contributed a median 1.3 years of follow-up (1,238 couple-years total), including 58,000 condomless sex acts (36,000 heterosexual and 22,000 MSM). Notably, zero phylogenetically linked HIV transmissions occurred within couples.

This result is remarkable and has stirred much discussion regarding the best interpretation. On one hand, it confirms findings of HPTN 052 regarding the drastically reduced HIV transmission risk with a suppressed viral load (defined liberally as less than 200 copies/ml in this trial) and fills in data gaps by including condomless sex (whereas reported condom use was very high in HPTN 052) and a large proportion of MSM couples (HPTN 052 included mostly heterosexual couples). On the other hand, as the authors point out, follow-up time and power are limited, and thus 95 percent confidence intervals make it difficult to definitively state that transmission risk is zero (particularly for anal sex with ejaculation, for which the upper limit is 20 percent over 10 years). Furthermore, as editorialists comment, a degree of selection bias may be present, and results are primarily generalizable to stable couples in which the positive partner has had excellent ART adherence for many years. 

So, how should we incorporate this data into counseling for serodifferent couples?  For most couples, this will involve an explanation of what we know and don’t know about HIV transmission risk and an individualized decision. Results of this study will add significantly to the counseling discussion and help us guide our patients and their partners to an informed decision, though we will likely still need to include small disclaimers when sharing the results. Outcomes of the PARTNER2 study, which will add data for MSM, are eagerly awaited.

(Rodger et al. JAMA. 2016 Jul 12;316(2):171-81.)

(Daar, Corado. JAMA. 2016 Jul 12;316(2):149-51.)

(Cohen et al. N Engl Med. 2016 Sep 1;375(9):830-9.)

Procalcitonin-Guided Therapy in Critically-Ill Patients
Reviewed by Zeina Kanafani, MD, MS

Antibiotics are frequently prescribed to critically ill patients for the treatment of various infections. It is often challenging for the clinician to determine the adequate duration of treatment, and antibiotics may be administered for a prolonged period of time, adding cost and contributing to antimicrobial resistance. Procalcitonin is an inflammatory maker with higher sensitivity and specificity than C-reactive protein; it has been used successfully in several studies to shorten the duration of treatment in the setting of respiratory tract infections and sepsis, although the safety of such an approach has not been fully vetted.

A recent article in Lancet Infectious Diseases describes an open-label, prospective, multicenter, randomized controlled trial conducted in the Netherlands. Adult patients in the intensive care unit with presumed infections requiring antibiotics were randomized to receive either procalcitonin-guided (n=761) or standard-of-care (n=785) antibiotic discontinuation. The intervention consisted of providing a non-binding advice to discontinue antibiotics once the procalcitonin concentration had decreased by 80 percent or more of its peak value or to £0.5 mg/L. The two primary endpoints of the trial were antibiotic daily defined doses (DDD) and duration of antibiotic treatment.

The investigators found a significantly lower median consumption of antibiotics in the procalcitonin-guided group compared to the standard-of-care group (7.5 vs. 9.3 DDD; p<0.0001). The median duration of treatment was also shorter in the procalcitonin-guided group (5 vs. 7 days; p<0.0001), thereby achieving the primary endpoints of the trial. In addition, the 28-day mortality was 20 percent in the procalcitonin-guided group and 27 percent in the standard-of-care group (p=0.0154), while the one-year mortality was 36 percent with procalcitonin and 43 percent with standard-of-care (p=0.0188).

The investigators therefore concluded that using guidance by procalcitonin for the discontinuation of antibiotics in critically ill patients is effective in reducing antibiotic usage. Not only was the safety of this approach confirmed, procalcitonin guidance was associated with a reduction in mortality rates.

(de Jong et al. Lancet Infect Dis. 2016; 16: 819–27.)

 

For a review of other recent research in the infectious diseases literature, see “In the Literature,” by Stanley Deresinski, MD, FIDSA, in each issue of Clinical Infectious Diseases:

September 15
  • Bacillus cereus Containing a Bacillus Anthracis Toxin Causing a Skin Legion
  • CANDIPOP: Is Fluconazole Effective as Initial Therapy in Patients With Candidemia Due to Candida glabrata?
September 1
  • Ophthalmology Consultation for Patients with Candidemia?
  • Is There Value in Antifungal Susceptibility Testing of Molds Other Than Aspergillus?
August 15
  • Aspergillosis Limited to the Orbit in Patients Without Identified Immunocompromise
  • Stenotrophomonas maltophilia: Antibiotic Choice